Core Binding Factor (CBF) abnormalities are associated with 20-25% of all acute myeloid leukemias (AML), of which 5-10% are further sub classified as acute myelomonocytic leukemia with eosinophilia,  also known as M4Eo in the FAB classification scheme.  This subtype of leukemia is usually associated with chromosome 16 inversion (p13:q22).  Chromosome 16 inversion results in formation of the fusion oncogene CBFB-MYH11, which encodes the fusion protein CBF-beta-SMMHC.  This fusion protein binds to RUNX1 (AML1) with high affinity and dominantly inhibits RUNX1 function preventing definitive hematopoiesis. It has been hypothesized that the interference of CBF-beta and RUNX1 binding could have therapeutic implications for patients with CBF mediated leukemias. We developed a CBF-beta and RUNX1 binding assay in AlphaScreenTM format and optimized it for high throughput screening to search for inhibitors.  The goal of this project is to screen MLPCN's compound collection (MLSMR) for identifying the inhibitors of the interaction between CBF-beta and RUNX1 proteins as research probes. If these probes work well in the animal models, the ultimate goal of this project is to development a new drug treatment for this disease. This assay can not be used to assess how apparent inhibitors interfere with protein binding, and whether inhibitors specifically bind to either protein. Disruption of this protein-protein interaction, through any mechanism, is the intended target activity. (1) Reagent, 3 uL CBFb-His/RUNX1-biotin mix incubated together for 20 minutes at room temperature (30 nM each) (2) Compound or control, 23 nL compound stock solution (3) Incubation, 15  minutes at Room temperature (4) Reagent, 1 uL 50 ng each of beads (Nickel beads and streptavidin beads) (5) Incubation, 90 minutes at Room temperature (6) Detection, Excitation=365 nm Emission=440 nm, Envision reader in AlphaScreenTM mode
bao:BAO_0000812 "1484" ; # "has summary assay" -> "1484"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000223 ; # "has assay format" -> "protein complex format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BAO_0000399 bao:BAO_0000282 ; # "has transcription factor" -> "transcription factor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_00020101 ; # "is bioassay type of" -> "protein-protein interaction assay"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "CBF-His/RUNX1-biotin" ; # "protein-protein" -> "CBF-His/RUNX1-biotin"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000130 ; # "has detection method" -> "alphascreen"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of inhibitors of the protein-protein interaction between the RUNX1 Runt domain and CBFb." ; # "screening campaign name" -> "Identification of inhibitors of the protein-protein interaction between the RUNX1 Runt domain and CBFb."
bao:BAO_0002853 "qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia" ; # "has assay title" -> "qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia"
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "90 minute" ; # "has incubation time value" -> "90 minute"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Paul Liu" ; # "material entity assay provider" -> "Paul Liu" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 "Core-binding factor subunit beta isoform 1" ; # "has participant" -> "Core-binding factor subunit beta isoform 1"
bao:BA0_0090012 "Runt-related transcription factor 1 (CBFa) isoform AML-1C" ; # "has participant" -> "Runt-related transcription factor 1 (CBFa) isoform AML-1C"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "865" ; # "gene ID" -> "865"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "861" ; # "gene ID" -> "861"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q13951-1" ; # "uniprot ID" -> "Q13951-1"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q01196-3" ; # "uniprot ID" -> "Q01196-3"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "865" ; # "construct gene ID" -> "865"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "861" ; # "construct gene ID" -> "861"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000877 ; # "has participant" -> "CBF-his/runx1-biotin protein complex"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "365 nanometer" ; # "has excitation wavelength value" -> "365 nanometer"
bao:BAO_0002918 "440 nanometer" ; # "has emission wavelength value" -> "440 nanometer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "23" ; # "has concentration-point number" -> "23"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie-2" ; # "Annotated by" -> "kunie-2"
